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Objective: Extensive marketing of devices for self-measurement of blood pressure has created 
a need for purchasers to be able to satisfy themselves that such devices have been evaluated 
according to agreed criteria. The Oregon Scientiﬁ  c BPU 330 blood pressure monitor is an 
electronic device for upper arm measurement. This study assessed the accuracy of the Oregon 
Scientiﬁ  c BPU 330 blood pressure monitor according to the International Protocol by the 
Working Group on Blood Pressure Monitoring of the European Society of Hypertension for 
validation of blood pressure measuring devices.
Method: 52 participants over 30 years of age were studied in the validation. Nine blood pressure 
measurements were taken alternately with a mercury sphygmomanometer by two observers, and 
by the supervisor, using the BPU 330 device. A total of 33 participants were selected for the 
analysis. The validation was divided into two phases. Phase 1 included 15 participants. If the 
device passed phase 1, 18 more participants were included. The 99 pairs of measurements were 
compared according to the International Protocol. The device was given a pass/fail recommenda-
tion based on its accuracy compared with the mercury standard (within 5, 10, and 15 mmHg), 
as well as the number met in the ranges speciﬁ  ed by the International Protocol.
Results: The mean and standard deviation of the difference between the mean of the observers 
and the BPU 330 device were 1.7 ± 4.7 mmHg and 2.8 ± 3.9 mmHg for systolic blood pressure 
(SBP) and diastolic blood pressure (DBP), respectively. In phase 1, the device passed with a total 
of 33, 43, and 44 SBP readings; 38, 44, and 45 DBP readings were within 5, 10, and 15 mmHg, 
respectively. In phase 2.1, 81, 95, and 96 for SBP, and 83, 95, and 98 for DBP readings fell 
within the zones of 5, 10, and 15 mmHg, respectively. In phase 2.2, the last phase, 28 partici-
pants fell within the zone of two of the three comparisons, lying within 5 mmHg for SBP and 
29 participants for DBP. No participants fell within the zone of all three of their comparisons 
over 5 mmHg apart for both SBP and DBP.
Conclusion: The BPU 330 can be recommended for self-monitoring of blood pressure in the 
adult population, according to the International Protocol.
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Introduction
Hypertension is an important public health challenge worldwide because of its high 
prevalence and the concomitant increase in risk of disease. It is the most important 
risk factor for cardiovascular, cerebrovascular, and renal disease (Kearney et al 2004). 
Self-monitoring of blood pressure (BP) is regarded as a useful adjunct to conventional 
ofﬁ  ce BP measurements (Stergiou et al 2007). Indeed, self-monitoring can provide 
valuable information on how the BP of patients under treatment is being controlled, 
and can improve patient compliance with antihypertension therapy (Assaad et al 2003). 
Extensive marketing of automated and semi-automated devices to manage BP enables Vascular Health and Risk Management 2008:4(5) 1122
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accurate and repeated BP measurements, which in turn aids 
in the identiﬁ  cation of patients suffering from high BP (Pini 
et al 2007). In 2002, the Working Group on Ambulatory Blood 
Pressure Monitoring of the European Society of Hyperten-
sion released its International Protocol for validation of 
BP-measuring devices in adults (O’Brien et al 2002). In com-
parison with the Association for the Advancement of Medical 
Instrumentation (AAMI 1993) and the British Hypertension 
Society (BHS; O’Brien et al 1993), the International Protocol 
has been simpliﬁ  ed in terms of sample size required and entry 
BP range. We used the International Protocol to perform a 
validation study of the Oregon Scientiﬁ  c BPU 330 (Oregon 
Scientiﬁ  c, Tualatin, USA), an upper arm BP monitor.
Method
Test device
The Oregon Scientiﬁ  c BPU330 is an upper arm BP monitor, 
which uses the oscillometric method of BP measurement. 
It measures BP at rest ranging between 30 and 280 mmHg, 
and pulse rate between 40 and 200 beats/min. Inﬂ  ation is 
performed by an automatic electric pumping system, and 
deﬂ  ation by automatic pressure-release valve. The device has 
a large liquid crystal display to show systolic and diastolic 
BP and heart rate and a memory capacity of 14 readings. It 
weighs about 340 g without batteries and measures 128 × 115 
× 64 mm. An arm cuff suitable for arm circumferences of 22 
to 42 cm is supplied with the device. The device is powered 
by four 1.5V batteries or an AC adaptor. A particular feature 
is the talking function to give voice instructions on how to 
use the device. After each measurement, the device reads out 
the BP value and interprets BP classiﬁ  cation according to 
World Health Organization (WHO) and International Society 
of Hypertension (ISH) guidelines (ISH 1999).
Participants
A total of 52 participants were measured in the validation study. 
According to the International Protocol, 33 participants were 
selected within the ranges of BP required in each category. 
Participants with arterial ﬁ  brillation and arrhythmias were 
excluded from the validation, whereas participants currently 
on pharmacological treatment for hypertension were included. 
Demographic data including age, sex, arm circumference, 
weight, height, and preexisting diseases were recorded. Table 1 
shows the participant number distributed in each BP range.
Procedure
One supervisor and two observers trained as described in 
Appendix B of the International Protocol conducted the 
validation study. The observers simultaneously measured 
BP using the auscultatory technique with standard mercury 
sphygmomanometer; the supervisor checked the values 
obtained by the observers and measured the BP with the 
test device.
The participant was introduced to the observers and the 
procedure explained. BP was measured in a warm quiet 
room. Arm and wrist circumference, sex, date of birth, and 
current date and time were noted. The participant was then 
asked to relax for 10–15 mins. BP was taken by the observers 
with a standard sphygmomanometer using a homologated 
two-headed binaural stethoscope. The supervisor measured 
BP with the test device, and checked the agreement of the 
measurement taken by the observers. The supervisor and 
observers were blinded to each other’s reading. Observ-
ers’ readings with a difference greater than 4 mmHg were 
repeated until closer agreement was reached. The aforesaid 
same measurements were not taken more than three times. 
All measurements were taken on the left arm, which was 
supported at heart level. At least 30 seconds were allowed 
between each measurement to avoid venous congestion, but 
no more than 60 seconds, to avoid increasing variability.
Nine sequential same-arm measurements using the test 
instrument and a standard mercury sphygmomanometer were 
recorded as follows:
BPA:    Entry BP was taken by observers 1 and 2 each with 
the mercury standard. The mean values were used to 
categorize the participant into a low, medium, or high 
range separately for SBP and DBP (Table 1).
BPB:    Device detection BP taken by the supervisor. This 
measurement was taken to allow the test instrument 
to determine the BP characteristics of the participant. 
More than one attempt may be needed with some 
devices; this measurement was not included in the 
analysis. If the device failed to record a measurement 
after three attempts, the participant was excused.
BP1:    Observers 1 and 2 with the mercury standard.
BP2:    Supervisor with the test instrument.
BP3:    Observers 1 and 2 with the mercury standard.
BP4:    Supervisor with the test instrument.
BP5:    Observers 1 and 2 with the mercury standard.
BP6:    Supervisor with the test instrument.
BP7:    Observers 1 and 2 with the mercury standard.
Analysis
For assessment of accuracy, only measurements BP1 to BP7 
were used. The mean of each pair of observer measurements Vascular Health and Risk Management 2008:4(5) 1123
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was calculated; these were denoted as observer measurements 
BP1, BP3, BP5, and BP7. Each device measurement was 
ﬂ  anked by two of these observer measurements. One of these 
was selected as the comparative measurement.
From these, further measurements were derived as 
follows.
1.  The differences between BP2 and BP1 (BP2–BP1), BP2–
BP3, BP4–BP3, BP4–BP5, BP6–BP5, and BP6–BP7 
were calculated.
2.  The absolute values of the differences were calculated.
3.  These were paired according to the device reading.
4.  If the values in a pair were unequal, the observer measure-
ment corresponding to the smaller difference was used.
5.  If the values in a pair were equal, the ﬁ  rst of the two 
observer measurements was used.
When this analysis was completed, there were three device 
readings for SBP and three for DBP for each participant.
The differences were classiﬁ  ed into three zones (within 
5, 10, and 15 mmHg), separately for SBP and DBP, for 
15 participants in phase 1 and all 33 participants in phase 
2.1. For phase 2.2, the number of differences of less than 
5 mmHg determined a pass/fail grade for 33 participants, 
and determined a pass/fail recommendation (Table 3). If the 
device failed at the ﬁ  rst phase, the validation was complete. 
To pass the validation and gain recommendation, a device 
had to pass both phase 2.1 and 2.2.
Result
A total of 52 participants were measured in the study. Par-
ticipants excluded consisted of 3 whose Korotkoff sound was 
too weak, 5 who opted out of the study before a complete 
measurement, 2 for whom the test BPU 330 gave repeat error 
readings, and 6 whose BP measurements were outside the 
BP ranges deﬁ  ned in the inclusion criteria. Three participants 
were excluded because the protocol-speciﬁ  ed BP category 
was already full. The characteristics of the 33 participants 
enrolled are shown in Table 2. The average age of the par-
ticipants was 46 ± 13 years (19 men and 14 women). The 
upper arm circumference was 36 ± 4 cm. The auscultatory 
BP measurements lay in the range 90–179 mmHg for SBP 
and 54–122 mmHg for DBP.
Table 1 Classiﬁ   cation of participants according to BP level
SBP (mmHg) DBP (mmHg) Participants (n)
Phase 1 Phase 2
Low 90–129 40–79 5 11
Medium 130–160 80–100 5 11
High 161–180 101–130 5 11
Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure.
Table 2 Characteristics of the study participants (n = 33)
Characteristics Mean ± SD Range
Age (years) 46 ± 13 30–78
Arm circumferences (cm) 36 ± 4 25–43
Weight (kg) 68 ± 14 48–96
Height (cm) 169 ± 11 155–186
Pulse rate (beat per min) 77 ± 11 61–108
Mean systolic pressure (mmHg) 144 ± 31 90–179
Mean diastolic pressure (mmHg) 88 ± 18 54–122
Table 3 Result of BPU 330
Phase1  5 mmHg  10 mmHg  15 mmHg Recomm.
Required One of 25 35 40
Achieved SBP 33 43 44 Continue
DBP 38 44 45 Continue
Phase 2.1  5 mmHg  10 mmHg  15 mmHg Recomm. MD SD
Required Two of 65 80 95
All of 60 75 90
Achieved SBP 81 95 96 Pass 1.7 4.7
DBP 82 95 98 Pass 2.8 3.9
Phase 2.2 2/3   5 mmHg 0/3   5 mmHg Recomm.
Required  22  3
Achieved SBP 28 0 Pass
DBP 29 0 Pass
Abbreviations: Recomm, recommendation; MD, mean difference (mmHg); SD, standard deviation (mmHg).Vascular Health and Risk Management 2008:4(5) 1124
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As shown in Table 3, a total of 33, 43, and 44 SBP readings 
and 38, 44, and 45 DBP readings in phase 1 were within 5, 10, 
and 15 mmHg, respectively. The device passed the require-
ments of phase 1 in the study group. In phase 2.1, 99 sets of 
measurements were available for analysis. In a sample of 33 
participants, 81, 95, and 96 for SBP and 82, 95, and 98 for 
DBP were within 5, 10, and 15 mmHg, respectively.
In the analysis conducted for the last phase (phase 2.2), 28 
participants had at least two of the differences within 5 mmHg 
for SBP and 29 participants had at least two of the differences 
within 5 mmHg for DBP. None fell in the zone of all three of 
their comparisons over 5 mmHg apart for both SBP and DBP. 
Thus the last phase was also successfully completed. The 
means and standard deviations of the difference between the 
means of the observers and BP device were 1.7 ± 4.7 mmHg 
and 2.8 ± 3.9 mmHg for SBP and DBP, respectively.
Bland-Altman plots of device–observer differences 
against the mean BP of device and observers are shown in 
Figure 1 for SBP and DBP, respectively.
Discussion
In recent years, self-monitoring of BP by patients at home 
is being increasingly used in clinical practice (Stergiou 
et al 2007). Patients and doctors increasingly use automatic 
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Plot of SBP difference between the BPU 330 and the
mean of the 2 observers in 33 participants(n=99)
Plot of DBP difference between the BPU 330 and the
mean of the 2 observers in 33 participants(n=99)
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Figure 1 Bland-Altman plots for systolic blood pressure (SBP) and diastolic blood pressure (DBP) (means of observers and device readings) versus the difference between 
the BPU 330 and the mercury sphygmomanometer.
Note: The stars indicate two measurements ; the square dots indicate three measurements.Vascular Health and Risk Management 2008:4(5) 1125
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devices for home BP monitoring (HBPM) (Omboni et al 
2007). HBPM has been shown to improve patient BP con-
trol, inform treatment decisions, and provide diagnostic as 
well as prognostic information (Viera and Hinderliter 2007). 
Moreover, HBPM is free of the white-coat effect, can detect 
the masked hypertension phenomenon and, compared to 
ofﬁ  ce BP measurements, is more reproducible, is correlated 
more closely to target organ damage, and better predicts 
cardiovascular events (Braam et al 2004; Greeff and Shennan 
2007). For this reason, the wide use of BP monitors at home 
is a consequence of the high value of self-monitoring of BP. 
Validation, accuracy assessment, and precision testing are 
still essential for each new device entering the market.
This study provides information on the accuracy and reli-
ability of the Oregon Scientiﬁ  c BPU 330 for self-monitoring 
of BP. It showed that the device comfortably fulﬁ  lled the 
validation requirements in accordance with the International 
Protocol. The BPU 330 device was accurate for both SBP and 
DBP, passing all phases of the International Protocol.
The average device-observer difference was lower than 
3 mmHg (1.7 for SBP and 2.8 for DBP) and the standard 
deviation of the device-observer difference was never greater 
than 5 mmHg (4.7 for SBP and 3.9 for DBP), indicating that 
the device is highly accurate.
The analysis shows that the BPU 330 provides accurate 
and reliable BP measurements and is capable of generating 
precise readings across a wide spectrum of participants. BPU 
330 can give voice instructions and provide memory. Each 
of these can help the user to record the BP history readings 
with date and time stamps, with the voice function. We 
therefore recommend that BPU 330 can be used as a home 
BP monitoring device for hypertension.
The BPU 330 can be recommended for self-monitoring 
of BP in the adult population according to the International 
Protocol.
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